PCOS: metabolic impact and long-term management

Minerva Ginecol. 2012 Dec;64(6):501-5.

Abstract

Polycystic ovary syndrome (PCOS) is the most frequent endocrinopathy in women, affecting up to 10% of those in reproductive age. Furthermore, PCOS presents a lifetime risk of type II diabetes, cardiovascular diseases and endometrial cancer. Women with PCOS have increased cardiovascular risk; however, the risk is not the same in all patients and it is necessary to assess an individual risk profile. There is a discrepancy between increased cardiovascular risk at young age and postmenopausal number of cardiovascular events, probablu depending on changes in androgen ovarian function after the forties. However, changes with age of metabolic profile in women with PCOS have not been studied yet and many more data are necessary.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adult
  • Antihypertensive Agents / therapeutic use
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / etiology
  • Child
  • Comorbidity
  • Diabetes Mellitus, Type 2 / epidemiology
  • Diabetes Mellitus, Type 2 / etiology
  • Diabetes Mellitus, Type 2 / physiopathology
  • Diabetes Mellitus, Type 2 / prevention & control
  • Dyslipidemias / drug therapy
  • Dyslipidemias / epidemiology
  • Dyslipidemias / etiology
  • Dyslipidemias / physiopathology
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypertension / drug therapy
  • Hypertension / etiology
  • Insulin Resistance
  • Metformin / therapeutic use
  • Obesity, Abdominal / epidemiology
  • Obesity, Abdominal / etiology
  • Obesity, Abdominal / physiopathology
  • Polycystic Ovary Syndrome / complications
  • Polycystic Ovary Syndrome / drug therapy
  • Polycystic Ovary Syndrome / epidemiology
  • Polycystic Ovary Syndrome / metabolism*
  • Risk Factors

Substances

  • Antihypertensive Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Metformin